A Retrospective Analysis of TKI Discontinuation in Patients with CML.
10.19746/j.cnki.issn.1009-2137.2021.06.009
- Author:
Xiao-Li ZHAO
1
;
Ming HONG
1
;
Chun QIAO
1
;
Qian SUN
1
;
Han ZHU
1
;
Shuai WANG
1
;
Jian-Yong LI
1
;
Si-Xuan QIAN
1
;
Yu ZHU
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital, Nanjing 210029, Jiangsu Province, China.
2. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital, Nanjing 210029, Jiangsu Province, China,E-mail:zhuyu@jsph.org.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*;
Protein Kinase Inhibitors;
Recurrence;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(6):1746-1751
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics of the patients with chronic myeloid leukemia (CML) discontinued tyrosine kinase inhibitors (TKI) therapy and the outcome of the patients.
METHODS:35 cases of CML patients experienced initiative discontinuation of TKI therapy in our hospital from June 1st 2015 to December 31th 2019 were retrospectively analyzed. The TFR of the patients and the factors affecting it were analyzed.
RESULTS:The median duration of TKI administration was 72 (range 35-173) months in the 35 patients. Among these patients, 8 had experienced TKI dose reduction or suspension. All the enrolled patients have achieved at least MMR. The median time for these patients achieving MMR was 15 (range 3-75) months after administration of TKI, and for MMR maintenance before TKI suspension was 55 (range 13-164) months. After TKI withdrawal the median follow up time was 20.3 (range 3-57.9) months, 22 out of 35 patients kept TFR, among them, 2 （5.71%） patients restarted TKI after 12 month suspension, and maintained MMR during suspension. 13 （37.1%）patients lost MMR, among them, 9 patients restarted TKI treatment, and 5 of them achieved MR4.0 after the median duration of 3(2-5) month. No patients were found to have disease progression. The estimated TFR rate was 57.8% and 51.8% at 12 and 24 months after discontinuation, respectively. Other clinical characteristic related to relapse were also analyzed, including the cumulative TKI administration duration, cumulative MMR duration, time to achieve MMR, median age at diagnosis, risk stratification by Sokal score, TKI dose reduction and discontinuation history, and second-generation TKI administration before stopping TKI, however, no statistical difference was found.
CONCLUSION:TKI discontinuation is practical for CML patients in our center.
